Understand the source comparison
How to Lower Blood Sugar Naturally With Peptides: Mechanism Comparison
The table below compares primary peptide classes used in glucose regulation research. Showing receptor targets, dosing ranges from published trials, expected glucose reduction, and key mechanistic differences. GLP-1 Agonists (semaglutide, liraglutide) GLP-1R o
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below compares primary peptide classes used in glucose regulation research. Showing receptor targets, dosing ranges from published trials, expected glucose reduction, and key mechanistic differences.
- GLP-1 Agonists (semaglutide, liraglutide)
- GLP-1R on pancreatic beta cells
- 0.5–2.4 mg weekly (semaglutide)
- 18–35 mg/dL
- Glucose-dependent insulin secretion + glucagon suppression + delayed gastric emptying
- Most direct glucose-lowering effect; well-characterised safety profile; requires slow titration to avoid GI side effects
- Dual GIP/GLP-1 Agonists (tirzepatide)
- GLP-1R + GIPR (pancreas & adipose)
- 5–15 mg weekly
- 25–45 mg/dL
- Dual incretin activation produces larger insulin response + enhanced lipolysis in adipose tissue
- Largest A1C reductions in head-to-head trials; superior to GLP-1 monotherapy but higher nausea rates during titration
- Growth Hormone Secretagogues (MK-677, ipamorelin)
- Ghrelin receptor (pituitary + hypothalamus)
- 10–25 mg daily (MK-677)
- Indirect (via insulin sensitivity)
- Increases GH/IGF-1 → promotes lipolysis → reduces hepatic/intramuscular fat → improves insulin sensitivity
- Indirect mechanism takes 8–12 weeks to produce measurable glucose effects; benefits sustained post-cessation unlike GLP-1
- Somatostatin Analogs (octreotide)
- SSTR2/SSTR5 (pancreatic islets)
- 50–200 mcg subcutaneous
- Variable (−10 to −30 mg/dL)
- Suppresses both insulin and glucagon; net effect depends on baseline pancreatic function
- Narrow therapeutic window; primarily used in research models of hyperinsulinemia or glucagonoma